NIH R01 · 2025
CAR neutrophils produced in vivo to remodel tumor microenvironment and treat glioblastoma
Project Summary Glioblastoma (GBM) is the most aggressive type of cancer that occurs in the brain. While functional anti- cancer therapeutics, such as emerging chimeric antigen receptor (CAR)-T and natural killer (NK) cell therapies, have been developed to treat various cancers, their therapeutic applications for brain cancers have been impeded by the blood-brain barrier (BBB) and immunosuppressive tumor microenvironment. Due to their native ability to cross BBB and penetrate the brain parenchyma, neutrophils have been recently used as carrier cells to deliver imaging and therapeutic drugs into brain tumors. Recently, the investigators engineered a GBM-targeted CAR-neutrophils from human…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.